

PlexPCR[®] RespiVirus

Two wells, 11 respiratory viruses

Increase productivity this flu season.




Highly multiplexed test offers workflow advantages to support influenza season surge


- ▶ Increase sample throughput compared with 3- or 4-well tests and run up to 1536 samples in 8 hours
- ▶ Free up senior laboratory staff with fast, reproducible data processing and automated results analysis

Increase respiratory virus testing throughput. 11 respiratory viruses in only 2 wells

- Flexible PCR plate format, choose from 96- and 384-well options
- 384-well format: up to **1536 samples** in 8 hrs with a single FTE[§]



Example of automation workflow



[§] 1 x FTE, 4 x MP96, 2 x LC480II utilising 384-well format and liquid handlers.

[‡] Time shown for 384-well set-up with 192 samples, time for 96-well set-up with 48 samples: 13 minutes

[◊] 10 µL reaction for 384-well set-up, 20 µL reaction for 96-well set-up


SpeedX Analysis for **PlexPCR**[®] RespiVirus

SpeedX Analysis software is included in contract pricing. Automate data processing and results interpretation for large numbers of samples simultaneously.

Speed up results processing and spend your time only on the few samples that require attention.

Automated plate set-up options for a streamlined workflow.

High security and GDPR compliant with LIS compatibility.



Comprehensive coverage in a 2-well test

- ▶ Detect 11 clinically relevant viral respiratory pathogens plus RNA-based Internal Control
- ▶ Increase the capacity of your qPCR instruments without compromising performance[†]
- ▶ Validated with nasopharyngeal swabs

[†]Contact tech@speedx.com.au for up-to-date QAP and QCMD data

PlexPCR® RespiVirus is a two-well multiplex qPCR test for the detection of 11 viral respiratory-illness causing pathogens plus RNA internal control.¹

Powered by proprietary **PlexPCR®** technologies demonstrating improved multiplex performance compared with other probe-based tests.²

Well	Channel	Target
1	1	Influenza A (FluA)
	2	Influenza B (FluB)
	3	Respiratory Syncytial Viruses A and B (RSV A and B)
	4	Rhinoviruses (RhV)
	5	Internal Control
2	1	Human metapneumovirus (hMPV)
	2	Adenoviruses B and C (AdV)
	3	Human parainfluenza viruses 1,2,3 and 4 (HPIV 1-4)

Validated with nasopharyngeal swabs only.¹

Demonstrated clinical performance¹

	FluA	FluB	RSV	RhV	hMPV	AdV	HPIV
Sensitivity	94.1%	98.0%	94.6%	96.7%	100%	100%	100%
Specificity	99.7%	99.4%	100%	96.6%	98.8%	99.7%	99.6%

Flexible platform compatibility

Sample extraction platforms	qPCR platforms
EasyMag (Biomérieux) Magna Pure 96 (Roche)	LC480 II 96 well LC480 II 384 well

Increase lab productivity this flu season
with **PlexPCR®** RespiVirus

Product	Compatible	Size	Cat#
PlexPCR® RespiVirus*	LC480 II	192 reactions	1201192
PlexPCR® RespiVirus Positive Control	All platforms	10 reactions	95002
PlexPCR® Colour Compensation	LC480 II	2 reactions	90001

References: 1. **PlexPCR®** RespiVirus Instructions for use. 2. Tan LY et al, PLOS ONE. 2017; 12(1): e0170087.

PlexPCR® RespiVirus kits are developed and manufactured by **SpeedX** Pty Ltd, Sydney. **PlexPCR®** & **SpeedX®** are registered trademarks of **SpeedX** Pty Ltd. Other copyright and trademarks are the property of the respective owners. **SpeedX** Pty. Ltd. products may be covered by one or more local or foreign patents. Visit www.speedxpcr.com/patents for comprehensive patent information.

Australia - SpeedX Pty. Ltd.

+61 (0)2 9209 4170

sales@speedx.com.au

Europe - SpeedX Ltd.

+44 (0)330 445 0036

sales.uk@speedx.com.au

Find out more speedxpcr.com

